SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 501.16 |
| Enterprise Value ($M) | 864.21 |
| Book Value ($M) | 847.47 |
| Book Value / Share | 30.29 |
| Price / Book | 0.59 |
| NCAV ($M) | -303.47 |
| NCAV / Share | -10.85 |
| Price / NCAV | -1.65 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.05 |
| Return on Assets (ROA) | -0.04 |
| Return on Equity (ROE) | -0.07 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.92 |
| Current Ratio | 1.96 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 594.59 |
| Assets | 1,745.53 |
| Liabilities | 898.06 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 2,882.22 |
| Operating Income | 41.78 |
| Net Income | -25.79 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 139.36 |
| Cash from Investing | -143.97 |
| Cash from Financing | -33.13 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Ameriprise Financial Inc | 5.93 | 34.29 | |
| 13G/A | Vanguard Group Inc | 9.40 | 0.48 | |
| 13G/A | Dimensional Fund Advisors Lp | 8.20 | 3.07 | |
| 13G/A | BlackRock Inc. | 12.10 | 13.20 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 50,125 | 294,396 | 17.03 | |
| 67,396 | 123,931 | 54.38 | |
| 40,666 | 113,354 | 35.88 | |
| 20,939 | 112,574 | 18.60 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| QNCX – Quince Therapeutics, Inc. | QURE – uniQure N.V. |
| RARE – Ultragenyx Pharmaceutical Inc. | REGN – Regeneron Pharmaceuticals, Inc. |
| REPL – Replimune Group, Inc. |